Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes

Clinical and Experimental Immunology

Volumn 177, Issue 1, 2014, Pages 149-160

  Castro, C N ^a   Barcala Tabarrozzi, A E ^a   Winnewisser, J ^a   Gimeno, M L ^a   Antunica Noguerol, M ^a   Liberman, A C ^a   Paz, D A ^b   Dewey, R A ^c   Perone, M J ^a,d  

^a CONICET Partner Institute of the Max Planck Society ^*  (Argentina)

^b INSTITUTO DE FISIOLOGÍA   (Argentina)

^c INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS   (Argentina)

^d Polo Científico Tecnológico   (Argentina)

Author keywords

Dendritic cells; Inflammation; NOD mouse; T lymphocytes; T bet

Indexed keywords

CURCUMIN; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; NITRIC OXIDE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR T BET;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CELL ACTIVITY; CELL DEATH; CELL INFILTRATION; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DIABETOGENESIS; DISEASE COURSE; DOWN REGULATION; EX VIVO STUDY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LEUKOCYTE; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MOUSE; NOD SCID MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATHOGENESIS; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

DENDRITIC CELLS; INFLAMMATION; NOD MOUSE; T LYMPHOCYTES; T-BET;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGEN PRESENTATION; ANTIOXIDANTS; CELLS, CULTURED; CURCUMIN; DENDRITIC CELLS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; NF-KAPPA B; T-BOX DOMAIN PROTEINS; TH1 CELLS; TRANSCRIPTIONAL ACTIVATION;

EID: 84904242865     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12322     Document Type: Article

References (59)

1. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331:1428-1436.
2. Roep BO, Kallan AA, De Vries RR. Beta-cell antigen-specific lysis of macrophages by CD4 T-cell clones from newly diagnosed IDDM patient. A putative mechanism of T-cell-mediated autoimmune islet cell destruction. Diabetes 1992; 41:1380-1384.
3. Davidson MH. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am J Cardiol 2012; 110:43B-49.
4. Reimann M, Bonifacio E, Solimena M etal. An update on preventive and regenerative therapies in diabetes mellitus. Pharmacol Ther 2009; 121:317-331.
5. Sosenko JM, Skyler JS, Palmer JP etal. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013; 36:2615-2620.
6. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009; 41:40-59.
7. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002; 168:6506-6513.
8. Motawi TK, Rizk SM, Shehata AH. Effects of curcumin and Ginkgo biloba on matrix metalloproteinases gene expression and other biomarkers of inflammatory bowel disease. J Physiol Biochem 2012; 68:529-539.
9. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012; 26:1719-1725.
10. Sun J, Zhao Y, Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLOS ONE 2013; 8:e67078.
11. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65:1631-1652.
12. Curic S, Wu Y, Shan B etal. Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas. J Neurooncol 2013; 113:385-396.
13. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann NY Acad Sci 2005; 1056:206-217.
14. Soetikno V, Sari FR, Veeraveedu PT etal. Curcumin ameliorates macrophage infiltration by inhibiting NF-kappaB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond) 2011; 8:35.
15. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008; 149:3549-3558.
16. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012; 35:2121-2127.
17. Kanai M, Yoshimura K, Asada M etal. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68:157-164.
18. Kanai M, Otsuka Y, Otsuka K etal. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 2013; 71:1521-1530.
19. Kanitkar M, Gokhale K, Galande S, Bhonde RR. Novel role of curcumin in the prevention of cytokine-induced islet death in vitro and diabetogenesis in vivo. Br J Pharmacol 2008; 155:702-713.
20. Chanpoo M, Petchpiboonthai H, Panyarachun B, Anupunpisit V. Effect of curcumin in the amelioration of pancreatic islets in streptozotocin-induced diabetic mice. J Med Assoc Thai 2010; 93 (Suppl. 6):S152-159.
21. Driver JP, Serreze DV, Chen YG. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol 2011; 33:67-87.
22. Perone MJ, Bertera S, Tawadrous ZS etal. Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. J Immunol 2006; 177:5278-5289.
23. Liberman AC, Antunica-Noguerol M, Ferraz-de-Paula V etal. Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells. PLOS ONE 2012; 7:e35155.
24. Liberman AC, Refojo D, Druker J etal. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J 2007; 21:1177-1188.
25. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655-669.
26. Perone MJ, Larregina AT, Shufesky WJ etal. Transgenic galectin-1 induces maturation of dendritic cells that elicit contrasting responses in naive and activated T cells. J Immunol 2006; 176:7207-7220.
27. Augstein P, Elefanty AG, Allison J, Harrison LC. Apoptosis and beta-cell destruction in pancreatic islets of NOD mice with spontaneous and cyclophosphamide-accelerated diabetes. Diabetologia 1998; 41:1381-1388.
28. Piganelli JD, Flores SC, Cruz C etal. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 2002; 51:347-355.
29. Roep BO, De Vries RR. T-lymphocytes and the pathogenesis of type 1 (insulin-dependent) diabetes mellitus. Eur J Clin Invest 1992; 22:697-711.
30. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99:351-358.
31. Barcala Tabarrozzi AE, Castro CN, Dewey RA, Sogayar MC, Labriola L, Perone MJ. Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus. Clin Exp Immunol 2013; 171:135-146.
32. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 1995; 206:533-540.
33. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976; 193:415-417.
34. Liu L, Liu YL, Liu GX etal. Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway. Int Immunopharmacol 2013; 17:314-320.
35. Ramirez-Tortosa MC, Mesa MD, Aguilera MC etal. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 1999; 147:371-378.
36. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21:8370-8377.
37. Joe B, Rao UJ, Lokesh BR. Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Mol Cell Biochem 1997; 169:125-134.
38. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980; 71:632-634.
39. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268:1185-1188.
40. Perone MJ, Bertera S, Shufesky WJ etal. Suppression of autoimmune diabetes by soluble galectin-1. J Immunol 2009; 182:2641-2653.
41. Fahey AJ, Adrian Robins R, Constantinescu CS. Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. J Cell Mol Med 2007; 11:1129-1137.
42. Williams CL, Schilling MM, Cho SH etal. STAT4 and T-bet are required for the plasticity of IFN-gamma expression across Th2 ontogeny and influence changes in ifng promoter DNA methylation. J Immunol 2013; 191:678-687.
43. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009; 39:216-224.
44. Bending D, De la Pena H, Veldhoen M etal. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009; 119:565-572.
45. Poligone B, Weaver DJ, Jr, Sen P, Baldwin AS, Jr, Tisch R. Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol 2002; 168:188-196.
46. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 1998; 188:2175-2180.
47. Kim GY, Kim KH, Lee SH etal. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 2005; 174:8116-8124.
48. Kang BY, Chung SW, Chung W, Im S, Hwang SY, Kim TS. Inhibition of interleukin-12 production in lipopolysaccharide-activated macrophages by curcumin. Eur J Pharmacol 1999; 384:191-195.
49. Kang BY, Song YJ, Kim KM, Choe YK, Hwang SY, Kim TS. Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol 1999; 128:380-384.
50. Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI. Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. Diabetes 2000; 49:1106-1115.
51. Marleau AM, Singh B. Myeloid dendritic cells in non-obese diabetic mice have elevated costimulatory and T helper-1-inducing abilities. J Autoimmun 2002; 19:23-35.
52. Morin J, Faideau B, Gagnerault MC, Lepault F, Boitard C, Boudaly S. Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)-4 and IL-10 in the spleen of recipient mice. Clin Exp Immunol 2003; 134:388-395.
53. Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors 2013; 39:27-36.
54. Rogers NM, Kireta S, Coates PT. Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo. Clin Exp Immunol 2010; 162:460-473.
55. Gerondakis S, Siebenlist U. Roles of the NF-kappaB pathway in lymphocyte development and function. Cold Spring Harbor Perspect Biol 2010; 2:a000182.
56. Curtsinger JM, Schmidt CS, Mondino A etal. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999; 162:3256-3262.
57. Pape KA, Khoruts A, Mondino A, Jenkins MK. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol 1997; 159:591-598.
58. Tse HM, Milton MJ, Schreiner S, Profozich JL, Trucco M, Piganelli JD. Disruption of innate-mediated proinflammatory cytokine and reactive oxygen species third signal leads to antigen-specific hyporesponsiveness. J Immunol 2007; 178:908-917.
59. Xavier S, Sadanandan J, George N, Paulose CS. Beta(2)-adrenoceptor and insulin receptor expression in the skeletal muscle of streptozotocin induced diabetic rats: antagonism by vitamin D(3) and curcumin. Eur J Pharmacol 2012; 687:14-20.